Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000023245
- Lead Sponsor
- Iwasaki Naika Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Type 1 diabetes 2. Patients with severe renal failure or liver dysfunction 3. Patients with drug allergy for ipraglifrozin 4. Patients with history of diabetec ketosis 5. Patients with shick day
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of HbA1c,body weight at the 12th and the 24th week.
- Secondary Outcome Measures
Name Time Method Change of data shown below at the 12th and the 24th week. AST, ALT, gamma-GTP, LDL-C, HDL-C,TG, non-HOL-C, serum creatinine, serum UA